IMPORTANT SAFETY INFORMATION FOR VOYDEYA
What is the most important information I should know about VOYDEYA?
VOYDEYA is a medicine that affects your immune system. VOYDEYA may
lower the ability of your immune system to fight infections.
-
VOYDEYA increases your chance of getting serious infections
caused by encapsulated bacteria. These serious infections may quickly become life-threatening and
cause death if not recognized and treated early.
-
You must complete or update meningococcal vaccine(s) and
streptococcus vaccine(s) at least 2 weeks before your first dose
of VOYDEYA.
-
If you have not completed your vaccinations and VOYDEYA must be
started right away, you should receive the required vaccinations
as soon as possible.
-
If you have not been vaccinated at least 2 weeks before your first
VOYDEYA dose and VOYDEYA must be started right away, you should
also receive antibiotics to take for as long as your healthcare
provider tells you.
-
If you have been vaccinated against these bacteria in the past,
you might need additional vaccinations before starting VOYDEYA.
Your healthcare provider will decide if you need additional
vaccinations.
-
Vaccines do not prevent all infections caused by encapsulated
bacteria. Call your healthcare provider or get emergency medical care
right away if you have any of these signs and symptoms of a
serious infection: fever with or without chills, fever and a rash, fever with chest
pain and cough, fever with breathlessness/fast breathing, fever with
high heart rate, headache with nausea or vomiting, headache and a fever,
headache with a stiff neck or stiff back, confusion, body aches with
flu-like symptoms, clammy skin, eyes sensitive to light.
Your healthcare provider will give you a Patient Safety Card
about the risk of serious infections. Carry it with you at all times during treatment and for 1 week after
your last VOYDEYA dose. Your risk of serious infections may continue
for a few days after your last dose of VOYDEYA. It is important to show
this card to any healthcare provider who treats you. This will help them
diagnose and treat you quickly.
VOYDEYA is only available through a program called the VOYDEYA
Risk Evaluation and Mitigation Strategy (REMS). Before you can take VOYDEYA, your healthcare provider must: enroll
in the VOYDEYA REMS; counsel you about the risk of serious infections
caused by certain bacteria; give you information about the symptoms of
serious infections; make sure that you are vaccinated against serious
infections caused by encapsulated bacteria and that you receive antibiotics
if you need to start VOYDEYA right away and you are not up to date on
your vaccinations; give you a Patient Safety Card about
your risk of serious infections, as discussed above.
Who should not receive VOYDEYA?
Do not take VOYDEYA if you have a serious infection
caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B infection.
Before taking VOYDEYA, tell your healthcare provider about all of
your medical conditions, including if you: have an infection or fever, have liver problems, are pregnant or plan
to become pregnant, or are breastfeeding. It is not known if VOYDEYA
will harm your unborn baby or if it passes into your breast milk. Do
not breastfeed during treatment with VOYDEYA and for 3 days after the
last dose.
Tell your healthcare provider about all the vaccines you receive
and medicines you take, including prescription and over-the-counter medicines, vitamins, and
herbal supplements which could affect your treatment. VOYDEYA may affect
the way other medicines work.
If you stop taking VOYDEYA, your healthcare provider
will need to monitor you closely for at least 2 weeks after your last
dose.
Stopping treatment with VOYDEYA may cause a breakdown of red
blood cells due to PNH. Symptoms or problems that can happen due
to breakdown of red blood cells include: decreased hemoglobin level in your blood and tiredness
What are the possible side effects of VOYDEYA?
VOYDEYA can cause serious side effects, including increased liver
enzyme levels and increased cholesterol. Your healthcare provider will do blood tests to check your liver enzyme
levels and cholesterol before and during treatment with VOYDEYA. Your
healthcare provider may temporarily or permanently stop treatment with
VOYDEYA if you develop increased liver enzyme levels.
The most common side effect of VOYDEYA is headache.
Tell your healthcare provider about any side effect that bothers you
or that does not go away. These are not all of the possible side
effects of VOYDEYA. For more information, ask your healthcare
provider or pharmacist. Call your healthcare provider for medical
advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.
INDICATION
What is VOYDEYA?
VOYDEYA is a prescription medicine used along with ravulizumab or
eculizumab to treat breakdown of red blood cells that takes place
outside of blood vessels (extravascular hemolysis), in adults with
paroxysmal nocturnal hemoglobinuria (PNH).
It is not known if VOYDEYA is safe and effective in children.
Please see the full Prescribing Information
and Medication Guide
for VOYDEYA, including Boxed WARNING regarding serious infections caused
by encapsulated bacteria.
IMPORTANT SAFETY INFORMATION FOR ULTOMIRIS
What is the most important information I should know about
ULTOMIRIS?
ULTOMIRIS is a medicine that affects your immune system and may
lower the ability of your immune system to fight infections.
-
ULTOMIRIS increases your chance of getting serious meningococcal
infections that may quickly become life-threatening or cause
death if not recognized and treated early.
-
You must complete or update meningococcal vaccine(s) at least 2
weeks before your first dose of ULTOMIRIS.
-
If you have not completed your meningococcal vaccines and
ULTOMIRIS must be started right away, you should receive the
required vaccine(s) as soon as possible.
-
If you have not been vaccinated and ULTOMIRIS must be started
right away, you should also receive antibiotics for as long as
your healthcare provider tells you.
-
If you had a meningococcal vaccine in the past, you might need
additional vaccines before starting ULTOMIRIS. Your healthcare
provider will decide if you need additional meningococcal
vaccines.
-
Meningococcal vaccines do not prevent all meningococcal
infections. Call your healthcare provider or get emergency medical care
right away if you get any of these signs and symptoms of a
meningococcal infection: fever, fever with high heart rate, headache and fever, confusion,
muscle aches with flu-like symptoms, fever and a rash, headache with
nausea or vomiting, headache with a stiff neck or stiff back, or eyes
sensitive to light.
Your healthcare provider will give you a Patient Safety Card
about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 8 months after
your last ULTOMIRIS dose. Your risk of meningococcal infection may continue
for several months after your last dose of ULTOMIRIS. It is important
to show this card to any healthcare provider who treats you. This will
help them diagnose and treat you quickly.
ULTOMIRIS is only available through a program called the
ULTOMIRIS and SOLIRIS Risk Evaluation and Mitigation Strategy
(REMS). Before you can receive ULTOMIRIS, your healthcare provider must: enroll
in the REMS program; counsel you about the risk of serious meningococcal
infections; give you information about the signs and symptoms of serious
meningococcal infection; make sure that you are vaccinated against serious
infections caused by meningococcal bacteria, and that you receive antibiotics
if you need to start ULTOMIRIS right away and are not up to date on your
vaccines; give you a Patient Safety Card about your
risk of meningococcal infection.
ULTOMIRIS may also increase the risk of other types of serious
infections, including Streptococcus pneumoniae, Haemophilus influenzae,
and Neisseria gonorrhoeae. Your child should receive vaccines
against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) if treated with ULTOMIRIS. Certain people may be at risk
of serious infections with gonorrhea.
Who should not receive ULTOMIRIS?
Do not receive ULTOMIRIS if you have a serious meningococcal
infection when you are starting ULTOMIRIS.
Before you receive ULTOMIRIS, tell your healthcare provider about
all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant,
and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS
will harm your unborn baby or if it passes into your breast milk. You
should not breastfeed during treatment and for 8 months after your final
dose of ULTOMIRIS.
Tell your healthcare provider about all the vaccines you receive
and medicines you take, including prescription and over-the-counter medicines, vitamins, and
herbal supplements which could affect your treatment.
If you have PNH and you stop receiving ULTOMIRIS, your healthcare
provider will need to monitor you closely for at least 16 weeks
after you stop ULTOMIRIS. Stopping ULTOMIRIS may cause breakdown
of your red blood cells due to PNH. Symptoms or problems that can
happen due to red blood cell breakdown include: drop in your red blood cell count, tiredness, blood in your urine,
stomach-area (abdomen) pain, shortness of breath, blood clots, trouble
swallowing, and erectile dysfunction (ED) in males.
What are the possible side effects of ULTOMIRIS?
ULTOMIRIS can cause serious side
effects including
infusion-related reactions. Symptoms of an infusion-
related reaction with ULTOMIRIS may include
lower back pain, abdominal pain, muscle spasms, changes in blood pressure,
tiredness, feeling faint, shaking chills (rigors), discomfort in your
arms or legs, bad taste, or drowsiness. Stop treatment of ULTOMIRIS and
tell your healthcare provider right away if you develop these symptoms,
or any other symptoms during your ULTOMIRIS
infusion that may mean you
are having a serious infusion-related reaction, including: chest pain,
trouble breathing or shortness of breath, swelling of your face, tongue,
or throat, and feel faint or pass out.
The most common side effects of ULTOMIRIS in people treated for
PNH are upper respiratory tract infection and headache.
Tell your healthcare provider about any side effect that bothers you
or that does not go away. These are not all the possible side
effects of ULTOMIRIS. For more information, ask your healthcare
provider or pharmacist. Call your healthcare provider right away if
you miss an ULTOMIRIS infusion or for medical advice about side
effects. You may report side effects to FDA at 1-800-FDA-1088
INDICATION
What is ULTOMIRIS?
ULTOMIRIS is a prescription medicine used to treat adults and
children 1 month of age and older with a disease called Paroxysmal
Nocturnal Hemoglobinuria (PNH).
It is not known if ULTOMIRIS is safe and effective in children
younger than 1 month of age.
Please see the full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious meningococcal
infections.
